Michael Etomi, MD
Nephrology · Charlotte, NCNPI 1720039787
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $171,214 of the $212,401 with a category attached, or 80.6%. Amgen accounts for 61.2% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $61,566, 2.9 times the $21,548 reported in 2019. Among nephrology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $506.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$130K
- Vifor Pharma, Inc.$77K
- GSK$3K
- Novartis$654
- Gilead$384
- Otsuka America Pharmaceutical, Inc.$379
- plus $2K from 15 others
What the payments were for
- Consulting fees$2,2751%
- Speaking & faculty fees$171,21481%
- Travel & lodging$28,51013%
- Food & beverage$10,0135%
- Education$3880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 221 | $129,951 |
| Vifor Pharma, Inc. | 109 | $76,698 |
| GSK | 4 | $2,539 |
| Novartis | 20 | $654 |
| Gilead | 4 | $384 |
| Otsuka America Pharmaceutical, Inc. | 12 | $379 |
| AstraZeneca | 8 | $276 |
| Calliditas Therapeutics US Inc. | 5 | $225 |
| Johnson & Johnson | 2 | $188 |
| Alnylam Pharmaceuticals Inc. | 3 | $166 |
| Boehringer Ingelheim | 7 | $165 |
| ANI Pharmaceuticals, Inc. | 7 | $135 |
| Novo Nordisk | 2 | $130 |
| Viiv Healthcare Company | 1 | $125 |
| OPKO Pharmaceuticals, LLC | 4 | $110 |
| Davol Inc. | 1 | $92 |
| Akebia Therapeutics Inc | 3 | $55 |
| Bayer | 3 | $54 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $33 |
| Travere Therapeutics, Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$212,401 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 24 | $25,237 |
| JardianceEmpagliflozin | 15 | $17,229 |
| FarxigaDapagliflozin Propanediol | 14 | $14,228 |
| Sevelamer Carbonate | 15 | $3,585 |
| Torsemide | 19 | $278 |
| Losartan Potassium | 35 | $259 |
| Calcitriol | 22 | $249 |
| Furosemide | 23 | $107 |
| Amlodipine Besylate | 27 | $99 |
| Carvedilol | 20 | $66 |
| Doxazosin Mesylate | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $165 | $17,22915 claims |
| AstraZenecaFarxiga | $276 | $14,22814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Charlotte
- Tomas Guerrero NunezCharlotte$6K
- George HartCharlotte$6K
- Gregory GreenwoodWinston-Salem$947K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
- James McCabeWilmington$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.